



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,181	09/09/2005	Judith A. Varner	UCSD-08879	5608
7590 Medlen & Carroll 101 Howard Street Suite 350 San Francisco, CA 94105		11/21/2007	EXAMINER NGUYEN, QUANG	
			ART UNIT 1633	PAPER NUMBER
			MAIL DATE 11/21/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/518,181

Applicant(s)

VARNER ET AL.

Examiner

Quang Nguyen, Ph.D.

Art Unit

1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 September 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 25-40 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 25-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 15 December 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>9/7/07</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's election without traverse of Group I, drawn to a method for reducing angiogenesis or for increasing apoptosis in a subject by expressing a nucleotide sequence encoding a protein comprising a protein kinase A catalytic subunit, in the reply filed on 9/7/07 is acknowledged. Applicants further elected the following species: (a) endothelial cell as a species of a cell; and (b) cancer as a species of a pathological condition.

New claims 25-40 are pending in the present application, and they are examined on the merits herein with the aforementioned elected species.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Art Unit: 1633

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 25-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kim et al. (J. Biol. Chem. 275:33920-33928, 2000: IDS) in view of Kim et al. (Biochem. Biophys. Res. Comm. 232:469-473, 1997), Srivastava et al. (Mol. Cell. Biol. 18:3509-3517, 1998) and Mixson, A. J. (US 6,080,728).

Kim et al already taught that agents that activate intracellular protein kinase A (PKA), such as forskolin, dibutyryl cAMP or $\alpha 5\beta 1$ antagonists, suppress endothelial cell migration on vitronectin *in vitro* or angiogenesis *in vivo*, while inhibitors of PKA reverse the anti-migratory or anti-angiogenic effects (see at least the abstract; page 33924, col. 2, last paragraph continues to first paragraph of col. 1 on page 33925; Figures 4-7). Kim et al further stated "These studies also suggest the potential use of PKA agonists in the treatment of angiogenic diseases, including cancer and arthritis" (page 33927, col. 2, last paragraph continues to first two lines in col. 1 of page 33928).

Kim et al did not teach specifically the use of an isolated nucleotide sequence encoding a protein comprising a protein kinase A (PKA) catalytic subunit as the agent or the PKA agonist in a method for reducing angiogenesis or for increasing apoptosis in a tissue comprising endothelial cells (elected species), and/or wherein the tissue is in a subject having cancer (elected species) as a pathological condition associated with angiogenesis.

However, at the effective filing date of the present application (6/25/02) Kim et al (Biochem. Biophys. Res. Comm. 232:469-473, 1997) already taught that

Art Unit: 1633

overexpression of a protein kinase A catalytic subunit mediated by a recombinant retroviral vector in SK-N-SH human neuroblastoma cells resulted in a 3-fold increased PKA activity in the absence of cAMP, increased type II protein kinase A activity and cellular growth inhibition (see at least the abstract; and Results and Discussion on pages 470-472).

Additionally, Srivastava et al taught that activation of cAMP-dependent protein kinase A by Paclitaxel, forskolin or okadaic acid induced Bcl2 hyperphosphorylation and apoptosis in cancer cells which were blocked by the PKA inhibitor Rp diastereomers of cAMP (see at least the abstract; page 3511, col. 2, the section entitled "cAMP-dependent protein kinase is involved in Bcl2 phosphorylation", page 3510, col. 2, the section entitled "Nuclear morphology").

Furthermore, at the effective filing date of the present application Mixson also taught successfully at least a method for inhibiting tumor growth in a subject bearing a tumor comprising injection of DNA encoding at least one anti-angiogenic protein or peptide specifically targeting the tumor and/or tumor vasculature (see at least Summary of the Invention; and issued claims). Mixson disclosed that the method is applicable to different types of tumors, including primary tumors and their metastases or malignant tumor cells, and all of the tumors are very dependent on blood supply to sustain their growth (col. 10, lines 15-19; col. 4, lines 47-54 and example 1).

Accordingly, it would have been obvious for an ordinary skilled artisan at the time of invention was made to modify the teachings of Kim et al (J. Biol. Chem. 275:33920-33928, 2000) by also expressing a nucleotide sequence encoding a protein comprising

Art Unit: 1633

a protein kinase A catalytic subunit in a tissue comprising endothelial cells, for example in a tumor vasculature, to induce anti-angiogenic effects and/or apoptotic effects to inhibit tumor growth in light of the teachings of Kim et al. (Biochem. Biophys. Res. Comm. 232:469-473, 1997), Srivastava et al., and Mixson, A. J.

An ordinary skilled artisan would have been motivated to carry out the above modification because expression a nucleotide encoding a protein kinase A catalytic subunit has been shown to be a means for the activation of intracellular protein kinase A that has been demonstrated to be involved in the suppression of endothelial cell migration on vitronectin *in vitro*, inhibiting angiogenesis *in vivo*, inhibiting human neuroblastoma cell growth *in vitro*, as well as the induction of Bcl2 hyperphosphorylation and apoptosis in cancer cells *in vitro*.

An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Kim et al (J. Biol. Chem. 275:33920-33928, 2000), Kim et al. (Biochem. Biophys. Res. Comm. 232:469-473, 1997), Srivastava et al. and Mixson, A. J.; coupled with a high level of skill of an ordinary artisan in the relevant art.

Thus, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., whose telephone number is (571) 272-0776.


Art Unit: 1633

If attempts to reach the examiner by telephone are unsuccessful, the examiner's SPE, Joseph T. Voitach, Ph.D., may be reached at (571) 272-0739.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633; Central Fax No. (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.


QUANG NGUYEN, PH.D.
PRIMARY EXAMINER